Skip to main content

Discovery of Potent Small Molecule Inhibitors of Mutant Isocitrate Dehydrogenase 1

Wednesday, September 13, 2017 — Poster Session I

12:00 p.m. – 1:30 p.m.
FAES Terrace


  • S Karavadhi
  • JM Rohde
  • R Pragani
  • M Davis
  • D Urban
  • N Martinez
  • T Lee
  • D Cheff
  • K Brimacombe
  • L Liu
  • M Henderson
  • S Titus
  • Y Fang
  • P Shah
  • J Covey
  • M Davis
  • M Hollingshead
  • WJ Moore
  • A Mclver
  • H Zheng


The mutated form of a key metabolic enzyme, isocitrate dehydrogenase (IDH), has emerged as a prominent oncology target given its prevalence in a diversity of cancers. The mutation of an active site arginine residue confers neomorphic activity to mutant isocitrate dehydrogenase (mIDH) and ultimately leads to the production of 2-hydroxyglutarate (2-HG), an oncometabolite which may be involved in the reprogramming of cells for tumorigenesis. In an effort to develop treatments for mIDH1 cancers, NCATS conducted a qHTS to identify inhibitors of both the R132H and the R132C IDH1 mutants. Subsequent medicinal chemistry optimization led to the discovery of potent inhibitors that minimize the production of 2-HG both in vitro and in vivo. Top compounds within this campaign continue to be interrogated in vivo in order to select a candidate for advancement into preclinical development.

Category: Chemical Biology